Argenx ((ARGX)) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Argenx is conducting a study titled A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis. The study aims to assess the effectiveness and safety of efgartigimod IV in treating active lupus nephritis in Chinese patients, a condition that significantly impacts kidney function.
The intervention being tested is efgartigimod IV, a biological treatment administered through intravenous infusions. Its purpose is to evaluate its potential as a therapeutic option for lupus nephritis.
This interventional study is designed as a randomized, parallel assignment with quadruple masking, meaning that participants, care providers, investigators, and outcomes assessors are all blinded. The primary goal is treatment-focused, aiming to establish proof of concept for efgartigimod’s efficacy and safety.
The study began on February 21, 2023, and is currently active but not recruiting. The last update was submitted on August 4, 2025. These dates are crucial as they indicate the study’s progress and timeline for potential results.
The update on this study could influence Argenx’s stock performance positively, as successful results might enhance investor confidence and position the company favorably against competitors in the lupus nephritis treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.